An Open-label, Multicenter Study of Ambrisentan and a Phosphodiesterase Type-5 Inhibitor Combination Therapy in Subjects With Pulmonary Arterial Hypertension Who Have Demonstrated a Sub-Optimal Response to a Phosphodiesterase Type-5 Inhibitor

Trial Profile

An Open-label, Multicenter Study of Ambrisentan and a Phosphodiesterase Type-5 Inhibitor Combination Therapy in Subjects With Pulmonary Arterial Hypertension Who Have Demonstrated a Sub-Optimal Response to a Phosphodiesterase Type-5 Inhibitor

Completed
Phase of Trial: Phase IV

Latest Information Update: 01 May 2017

At a glance

  • Drugs Ambrisentan (Primary)
  • Indications Pulmonary arterial hypertension
  • Focus Therapeutic Use
  • Sponsors Gilead Sciences
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 01 May 2017 Primary endpoint (Change From Baseline in Pulmonary Vascular Resistance (PVR), Last Observation Carried Forward (LOCF)) has been met. (Change From Baseline in Pulmonary Vascular Resistance (PVR), Last Observation Carried Forward (LOCF))
    • 01 May 2017 Results (n=33) assessing safety and efficacy of addition of ambrisentan in patients who received ambrisentan and did not receive placebo, published in the Respiratory Medicine
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top